Expert opinion on current and emerging treatment options in androgenetic alopecia and telogen effluvium: an Indian perspective

Authors

  • Bharat Lalwala Lalwala Skin, Hair Transplant Centre, Surat, Gujarat, India
  • Siddhartha Das Dr. Siddhartha Das, Orchid Skin Clinic, Kolkata, West Bengal, India
  • Srinivasa Murthy Skin & Cosmetology Centre, Bangalore, Karnataka, India
  • Abir Saraswat Indushree Skin Clinic, Lucknow, Uttar Pradesh, India
  • U. R. Dhanalakshmi Dr. Dhanalakshmi Skin Clinic, Chennai, Tamil Nadu, India
  • Mukesh Girdhar Dr Girdhar’s Skin Clinic, Karkardooma, Delhi, India
  • Sachin Dhawan Skin n’ Smiles, Gurugram, Delhi, India
  • Kamal Jhamnani Abhiridh Specialty Clinic, Secunderabad, Telangana, India
  • Deepa Kanchankoti Myskin Laser Clinic, Kandivali (East), Mumbai, Maharashtra, India
  • Sushil Pande Department of Dermatology, NKP Salve Institute of Medical Sciences and Lata Mangeshkar Hospital, Nagpur Maharashtra, India

DOI:

https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20214926

Keywords:

Androgenetic alopecia, Telogen effluvium, Management, Treatment, Nutritional therapy

Abstract

The diagnosis and management of hair loss needs an organized and systematic approach for recognizing pattern of hair loss and identification of hair loss etiology. Early and specific diagnosis is essential to initiate appropriate treatment in the early phases of hair loss. Topical minoxidil and oral finasteride are the only approved drugs for androgenetic alopecia (AGA). Various other treatment options are widely used but have limited clinical evidence. Similarly, there are no specific treatments recommended for telogen effluvium (TE). However, the treatment may become challenging with increasing availability of new formulations and drugs with no substantial evidence to support them. Multiple focused group discussions were conducted among Indian dermatologists to gain expert opinion on appropriate management of AGA and TE in the current scenario. This article summarizes the consensus clinical viewpoints for topical and oral medications, role of nutritional supplements, and other adjunctive therapies in managing AGA and TE. The panel highlighted that the choice of treatment for AGA and TE depends on the individual hair loss pattern and response to medications. A brief discussion on the use of shampoos and procedures has also been highlighted.  

References

Phillips TG, Slomiany WP, Allison R. Hair loss: Common causes and treatment. Am Fam Physician. 2017;96:371-8.

Fabbrocini G, Cantelli M, Masarà A, Annunziata MC, Marasca C, Cacciapuoti S. Female pattern hair loss: A clinical, pathophysiologic, and therapeutic review. Int J Womens Dermatol. 2018;4:203-11.

Trüeb RM. The difficult hair loss patient: a particular challenge. Int J Trichology. 2013;5:110-4.

Kanti V, Messenger A, Dobos G, Reygagne P, Finner A, Blumeyer A, et al. Evidence‐based (S3) guideline for the treatment of androgenetic alopecia in women and in men–short version. J Eur Acad Dermatol Venereol. 2018;32:11-22.

Kaliyadan F, Nambiar A, Vijayaraghavan S. Androgenetic alopecia: an update. Indian J Dermatol Venereol Leprol. 2013;79:613-25.

Siah TW, Muir-Green L, Shapiro J. Female pattern hair loss: A retrospective study in a tertiary referral center. Int J Trichology. 2016;8:57-61.

Malkud S. A hospital-based study to determine causes of diffuse hair loss in women. J Clin Diagn Res. 2015;9:WC01-4.

Malkud S. Telogen effluvium: A review. J Clin Diagn Res. 2015;9:WE01-3.

Wohltmann WE, Sperling L. Histopathologic diagnosis of multifactorial alopecia. J Cutan Pathol. 2016;43:483-91.

Varothai S, Bergfeld WF. Androgenetic alopecia: An evidence-based treatment update. Am J Clin Dermatol. 2014;15:217-30.

Olsen EA, Dunlap FE, Funicella T, Koperski JA, Swinehart JM, Tschen EH, et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2002;47:377-85.

Ghonemy S, Alarawi A, Bessar H. Efficacy and safety of a new 10% topical minoxidil versus 5% topical minoxidil and placebo in the treatment of male androgenetic alopecia: a trichoscopic evaluation. J Dermatol Treat. 2021;2:236-41.

Purnak T, Senel E, Sahin C. Liquid formulation of minoxidil versus its foam formulation. Indian J Dermatol. 2011;56:462.

Rossi A, Cantisani C, Melis L, Iorio A, Scali E, Calvieri S. Minoxidil use in dermatology, side effects and recent patents. Recent Pat Inflamm Allergy Drug Discov 2012;6:130-6

Gogtay JA, Panda M. Minoxidil topical foam: A new kid on the block. Int J Trichology. 2009;1:142.

Thuangtong R, Thanomkitti K, Suvanasuthi S. A comparative study between the efficacy and safety of 5% minoxidil solution and 5% minoxidil milky lotion in the treatment of male androgenic alopecia. J Med Assoc Thai. 2017;100:70-7.

Suchonwanit P, Thammarucha S, Leerunyakul K. Minoxidil and its use in hair disorders: a review. Drug Des Devel Ther. 2019;13:2777-86.

Chandrashekar BS, Nandhini T, Vasanth V, Sriram R, Navale S. Topical minoxidil fortified with finasteride: An account of maintenance of hair density after replacing oral finasteride. Indian Dermatol Online J. 2015;6:17-20.

Tanglertsampan C. Efficacy and safety of 3% minoxidil versus combined 3% minoxidil / 0.1% finasteride in male pattern hair loss: a randomized, double-blind, comparative study. J Med Assoc Thai. 2012;95:1312-16.

Hu R, Xu F, Sheng Y, Qi S, Han Y, Miao Y, et al. Combined treatment with oral finasteride and topical minoxidil in male androgenetic alopecia: a randomized and comparative study in Chinese patients. Dermatol Ther. 2015;28:303-8.

Suchonwanit P, Iamsumang W, Rojhirunsakool S. Efficacy of topical combination of 0.25% finasteride and 3% minoxidil versus 3% minoxidil solution in female pattern hair loss: A randomized, double-blind, controlled study. Am J Clin Dermatol. 2019;20:147-53.

Karaca N, Akpolat ND. A comparative study between topical 5% minoxidil and topical “redensyl, capixyl, and procapil” combination in men with androgenetic alopecia. J Cosmo Trichol. 2019;5:1-7.

Loing E, Lachance R, Ollier V, Hocquaux M. A new strategy to modulate alopecia using a combination of two specific and unique ingredients. J Cosmet Sci. 2013;64:45-58.

Kwon OS, Pyo HK, Oh YJ, Han JH, Lee SR, Chung JH, et al. Promotive effect of minoxidil combined with all-trans retinoic acid (tretinoin) on human hair growth in vitro. J Korean Med Sci. 2007;22:283-9.

Ferry JJ, Forbes KK, VanderLugt JT, Szpunar GJ. Influence of tretinoin on the percutaneous absorption of minoxidil from an aqueous topical solution. Clin Pharmacol Ther. 1990;47:439-46.

Stamatiadis D, Bulteau-Portois MC, Mowszowicz I. Inhibition of 5 alpha-reductase activity in human skin by zinc and azelaic acid. Br J Dermatol 1988;119:627-32

Mysore V, Parthasaradhi A, Kharkar RD, Ghoshal AK, Ganjoo A, Ravichandran G, et al. Expert consensus on the management of Telogen Effluvium in India. Int J Trichology. 2019;11:107-12.

Hosking AM, Juhasz M, Mesinkovska AN. Complementary and alternative treatments for alopecia: A comprehensive review. Skin Appendage Disord. 2019;5:72-89.

Fischer TW, Burmeister G, Schmidt HW, Elsner P. Melatonin increases anagen hair rate in women with androgenetic alopecia or diffuse alopecia: results of a pilot randomized controlled trial. Br J Dermatol. 2004;150:341-5.

Oura H, Iino M, Nakazawa Y, Tajima M, Ideta R, Nakaya Y, et al. Adenosine increases anagen hair growth and thick hairs in Japanese women with female pattern hair loss: a pilot, double-blind, randomized, placebo-controlled trial. J Dermatol. 2008;35:763-7.

Sorbellini E, Pinto D, Marzani B, Rinaldi F. Drug treatment for androgenetic alopecia: First Italian questionnaire survey on what dermatologists think about finasteride. Dermatol Ther (Heidelb). 2018;8:259-67.

Mysore V, Shashikumar BM. Guidelines on the use of finasteride in androgenetic alopecia. Indian J Dermatol Venereol Leprol. 2016;82:128-34.

Iorizzo M, Vincenzi C, Voudouris S, Piraccini BM, Tosti A. Finasteride treatment of female pattern hair loss. Arch Dermatol. 2006;142:298-302.

Oliveira-Soares R, E Silva JM, Correia MP, André MC. Finasteride 5 mg/day treatment of patterned hair loss in normo-androgenetic postmenopausal women. Int J Trichology. 2013;5:22-5.

Guo EL, Katta R. Diet and hair loss: effects of nutrient deficiency and supplement use. Dermatol Pract Concept. 2017;7:1-10.

Goluch-Koniuszy ZS. Nutrition of women with hair loss problem during the period of menopause. Prz Menopauzalny. 2016;15:56-61.

Bansal M, Manchanda K, Pandey SS. Role of caffeine in the management of androgenetic alopecia. Int J Trichology. 2012;4:185-86.

Jimenez-Cauhe J, Saceda-Corralo D, Rodrigues-Barata R, Hermosa-Gelbard A, Moreno-Arrones OM, Fernandez-Nieto D, et al. Effectiveness and safety of low-dose oral minoxidil in male androgenetic alopecia. J Am Acad Dermatol. 2019;81:648-9.

Beach RA. Case series of oral minoxidil for androgenetic and traction alopecia: Tolerability & the five C's of oral therapy. Dermatol Ther. 2018;31:e12707.

Rizer RL, Stephens TJ, Herndon JH, Sperber BR, Murphy J, Ablon GR. A marine protein-based dietary supplement for subclinical hair thinning/loss: results of a multisite, double-blind, placebo-controlled clinical trial. Int J Trichology. 2015;7:156-66.

Kwon OS, Han JH, Yoo HG, Chung JH, Cho KH, Eun HC, et al. Human hair growth enhancement in vitro by green tea epigallocatechin-3-gallate (EGCG). Phytomedicine. 2007;14:551-55.

Harada N, Okajima K, Arai M, Kurihara H, Nakagata N. Administration of capsaicin and isoflavone promotes hair growth by increasing insulin-like growth factor-I production in mice and in humans with alopecia. Growth Horm IGF Res. 2007;17:408-15.

Rajput R. The Concept of Cyclical Nutritional Therapy for Hair Growth which can be Applied for Wellness. J Nutr Food Sci. 2017;7:615.

Trüeb RM, Henry JP, Davis MG, Schwartz JR. Scalp Condition Impacts Hair Growth and Retention via Oxidative Stress. Int J Trichol. 2018;10:262-70.

Piérard-Franchimont C, Goffin V, Henry F, Uhoda I, Braham C, Piérard GE. Nudging hair shedding by antidandruff shampoos. A comparison of 1% ketoconazole, 1% piroctone olamine and 1% zinc pyrithione formulations. Int J Cosmet Sci. 2002;24:249-56.

Sinclair R, Patel M, Dawson Jr TL, Yazdabadi A, Yip L, Perez A, et al. Hair loss in women: medical and cosmetic approaches to increase scalp hair fullness. Br J Dermatol. 2011;165:12-8.

Jang WS, Son IP, Yeo IK, Park KY, Li K, Kim BJ, et al. The annual changes of clinical manifestation of androgenetic alopecia clinic in Korean males and females: a outpatient-based study. Ann Dermatol. 2013;25:181-8.

Godse K, Zawar V. Sensitive scalp. Int J Trichology. 2012;4:102-4.

Saed S, Ibrahim O, Bergfeld WF. Hair camouflage: A comprehensive review. Int J Womens Dermatol. 2017; (1):S75-80.

Kartal SP, Altunel C, Gencler B. Cosmetic procedures in the treatment of alopecia. Hair and scalp disorders. 2017;3:317.

Downloads

Published

2021-12-24

Issue

Section

Review Articles